2 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Bioxodes S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage Ir-CPI - Intracerebral Hemorrhage | Phase 2 | Completed | Bioxodes S.A. | 23 | 2023-11-17 | 2026-07-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects Ir-CPI - Dose 1, Ir-CPI - Dose 2, Ir-CPI - Dose 3 - Healthy | Phase 1 | Completed | Bioxodes S.A. | 32 | 2019-09-12 | 2023-02-23 |
Cerebral Hemorrhage (1) · Cerebrovascular Disorders (1) · Inflammation (1) · Intracranial Hemorrhages (1) · Neuroinflammatory Diseases (1) · Stroke (1)
Belgium (2)
2019 (1)